MedTrace Logo

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

NCT00497159 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2015-06-08

No results posted yet for this study

Summary

This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.

Conditions

Interventions

OTHER

Placebo

Placebo TID x 90 days

DRUG

Dimebon

Dimebon 20 mg TID x 90 days

Sponsors & Collaborators

  • Huntington Study Group

    collaborator NETWORK

  • Medivation, Inc.

    lead INDUSTRY

Principal Investigators

  • Karl Kieburtz, MD, MPH · Huntington Study Group, University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497159 on ClinicalTrials.gov